+40.0%
PATH vs MRNA
+511.3%
-471.3%
-51.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -16.6% | -2.2% | -14.4% | -16.6% |
| 7D | -16.3% | +5.5% | -21.8% | -16.4% |
| 30D | +9.9% | +158.7% | -148.8% | +3.8% |
| 3M | +30.2% | +182.1% | -152.0% | +21.2% |
| 6M | +37.2% | +151.8% | -114.6% | +30.0% |
| YTD | -7.3% | +393.6% | -400.9% | -24.5% |
| 1Y | +40.0% | +499.5% | -459.5% | +5.0% |
| All | +40.0% | +511.3% | -471.3% | +5.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling